CNS Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	9.86	6.46	0.55	10.06	5	14.04
Cash & Short-Term Investments	9.86	6.46	0.55	10.06	5	14.04
Cash Growth	41.46%	1077.53%	-94.54%	100.93%	-64.35%	93.88%
Other Receivables	-	0.88	-	-	-	-
Receivables	-	0.88	-	-	-	-
Prepaid Expenses	1.48	1.29	0.84	2.51	2.47	1.46
Other Current Assets	0.04	0.02	0.2	-	-	-
Total Current Assets	11.39	8.66	1.59	12.56	7.48	15.5
Property, Plant & Equipment	0	0.01	0	0.01	0.02	0.02
Long-Term Deferred Charges	-	-	-	-	0.33	0.33
Other Long-Term Assets	0.47	0.04	0.1	0.48	0.93	-
Total Assets	11.87	8.7	1.7	13.05	8.76	15.85
Accounts Payable	1.93	2.2	5.83	4.51	1.98	0.95
Accrued Expenses	-	-	-	-	0.22	0.52
Short-Term Debt	0.03	0.33	0.3	0.41	0.39	0.44
Total Current Liabilities	1.96	2.52	6.13	4.92	2.59	1.91
Total Liabilities	1.96	2.52	6.13	4.92	2.59	1.91
Common Stock	0	0	0	0	0	0.02
Additional Paid-In Capital	104.23	90.6	65.13	58.85	41.6	34.87
Retained Earnings	-94.32	-84.42	-69.57	-50.72	-35.44	-20.95
Shareholders' Equity	9.91	6.18	-4.43	8.13	6.16	13.95
Total Liabilities & Equity	11.87	8.7	1.7	13.05	8.76	15.85
Total Debt	0.03	0.33	0.3	0.41	0.39	0.44
Net Cash (Debt)	9.83	6.14	0.25	9.65	4.62	13.6
Net Cash Growth	41.65%	2374.76%	-97.43%	108.92%	-66.05%	87.81%
Net Cash Per Share	31.48	192.61	-	-	-	-
Filing Date Shares Outstanding	0.62	0.25	-	-	-	-
Total Common Shares Outstanding	0.57	0.12	-	-	-	-
Working Capital	9.43	6.13	-4.54	7.64	4.88	13.59
Book Value Per Share	17.25	52.43	-	-	-	-
Tangible Book Value	9.91	6.18	-4.43	8.13	6.16	13.95
Tangible Book Value Per Share	17.25	52.43	-	-	-	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q